TTPH - Tetraphase Pharma Summary, Stock Quote and News

2.290 0 (0%)

Data as of Dec 16, 2019

Prev. Close 2.29
Price Open
Volume 0
Day's Range -
52 Wk Range 2.06 - 33.6
50 Day Moving Avg. 3.28
PE Ratio 0
Shares Outstanding 3.02M
Market Cap 6.91M

Trade TTPH stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Research Firm	Action	Current	Target
10/31/19	Gabelli & Co.	Upgrades	HoldBuy	5.0
9/03/19	H.C. Wainwright	Downgrades	BuyNeutral
3/18/19	Gabelli & Co.	Downgrades	BuyHold

The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win Shanthi RexalineThu, 12 Dec 2019 07:38:44 -0500
The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint Shanthi RexalineWed, 11 Dec 2019 07:21:31 -0500
Stocks That Hit 52-Week Lows On Tuesday Lisa LevinTue, 10 Dec 2019 14:29:37 -0500
24 Stocks Moving in Tuesday's Pre-Market Session Lisa LevinTue, 26 Nov 2019 07:55:49 -0500
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data Shanthi RexalineWed, 20 Nov 2019 07:25:05 -0500
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Shanthi RexalineFri, 15 Nov 2019 07:08:29 -0500
The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing Shanthi RexalineThu, 14 Nov 2019 08:07:04 -0500
81 Biggest Movers From Yesterday Lisa LevinThu, 14 Nov 2019 05:20:47 -0500
Stocks That Hit 52-Week Lows On Wednesday Lisa LevinWed, 13 Nov 2019 10:50:38 -0500
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher Shanthi RexalineWed, 13 Nov 2019 07:10:18 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Tetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Developments Business WireNov 12, 2019
Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call Business WireNov 05, 2019
Tetraphase Pharmaceuticals Announces Completion of $8 Million Registered Direct Offering Priced At-the-Market Business WireNov 01, 2019
Tetraphase Pharmaceuticals Announces $8 Million Registered Direct Offering Priced At-the-Market Business WireOct 30, 2019
Tetraphase Pharmaceuticals Announces Reverse Stock Split Business WireSep 26, 2019
Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019 Business WireSep 25, 2019
Tetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference Business WireSep 03, 2019
Tetraphase Pharmaceuticals Reports Second Quarter 2019 Financial Results and Highlights Recent Corporate Developments Business WireAug 08, 2019
Tetraphase Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call Business WireAug 01, 2019
New Studies Highlight Activity of XERAVA™ Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens Business WireJun 24, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q3 2019 Results - Earnings Call Transcript Seeking AlphaNov 12, 2019
Tetraphase Pharmaceuticals (TTPH) Reports Q3 Loss, Tops Revenue Estimates ZacksNov 12, 2019
Tetraphase Pharmaceuticals EPS beats by $0.70, misses on revenue Seeking AlphaNov 12, 2019
Dow Chemical Co Buys Lyft Inc, Consumer Staples Select Sector SPDR Fund, Energy Select Sector ... GuruFocusNov 08, 2019
US Stock Market Weekly Update October 28-November 1, 2019 TalkMarketsNov 03, 2019
Gabelli likes TetraPhase Pharma in premarket analyst action Seeking AlphaOct 31, 2019
Tetraphase down 12% premarket on equity offering Seeking AlphaOct 30, 2019
AIMT, AYI, NIO and TSG among midday movers Seeking AlphaOct 02, 2019
DURECT and Aimmune Therapeutics among healthcare gainers; Savara leads the losers Seeking AlphaOct 02, 2019
Tetraphase Pharma up 23% after reverse split Seeking AlphaSep 27, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q3 2019	EST	Actual	Surprise
EPS:	-6.700	-6.000	0.7000
Rev:	3.52M	3.34M	-180.00K

Q4 2019	EST	Actual	Surprise
EPS:	Expected 2020-03-12
Rev:	Expected 2020-03-12

Company Profile

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners